The present invention relates to a process for the preparation of iloprost of formula I through new intermediates, isolation of iloprost of formula I in solid form, as well as preparation of the 16(S)-iloprost and 16(R)-iloprost isomers of formulae (S)-I and (R)-I and isolation of iloprost of formula I and 16(S)-iloprost of formula (S)-I in solid, crystalline form. ##STR00001##

The present invention relates to a process for the preparation of iloprost of formula I through new intermediates, isolation of iloprost of formula I in solid form, as well as preparation of the 16(S)-iloprost and 16(R)-iloprost isomers of formulae (S)-I and (R)-I and isolation of iloprost of formula I and 16(S)-iloprost of formula (S)-I in solid, crystalline form. ##STR00001##

The present invention relates to a process for the preparation of iloprost of formula I through new intermediates, isolation of iloprost of formula I in solid form, as well as preparation of the 16(S)-iloprost and 16(R)-iloprost isomers of formulae (S)-I and (R)-I and isolation of iloprost of formula I and 16(S)-iloprost of formula (S)-I in solid, crystalline form. ##STR00001##

The present disclosure provides a process for the preparation of compounds of formula (III),

##STR00001##

compounds of formula (V),

##STR00002##

and corresponding salts of formula (IV).

##STR00003##

The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

The present disclosure provides a process for the preparation of compounds of formula (III),

##STR00001##

compounds of formula (V),

##STR00002##

and corresponding salts of formula (IV).

##STR00003##

The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

The present disclosure provides a process for the preparation of compounds of formula (III),

##STR00001##

compounds of formula (V),

##STR00002##

and corresponding salts of formula (IV).

##STR00003##

The compounds made by the methods and processes of the invention are particularly useful for administration in humans and animals.

An apparatus for depolymerization of polymers, in particular polyesters, polyamides, polyurethanes and polycarbonates, comprises a microwave depolymerization reactor having a reaction chamber; a microwave generation and transport system to send microwaves into the reaction chamber and comprising a microwave generator and a guide device housed in the reaction chamber to convey and distribute microwaves in the reaction chamber; a mixing device, rotating around the axis in the reaction chamber and configured so as to dynamically distribute inside the reaction chamber a mixture of liquids and solids contained in the reaction chamber; and a pressurization system configured to vary the pressure within the reaction chamber.

An apparatus for depolymerization of polymers, in particular polyesters, polyamides, polyurethanes and polycarbonates, comprises a microwave depolymerization reactor having a reaction chamber; a microwave generation and transport system to send microwaves into the reaction chamber and comprising a microwave generator and a guide device housed in the reaction chamber to convey and distribute microwaves in the reaction chamber; a mixing device, rotating around the axis in the reaction chamber and configured so as to dynamically distribute inside the reaction chamber a mixture of liquids and solids contained in the reaction chamber; and a pressurization system configured to vary the pressure within the reaction chamber.

The present invention discloses a cyclohexenecarboxylate ester hydrolase, and a mutant, a coding gene, an expression vector, recombinant bacterium and use thereof. The cyclohexenecarboxylate ester hydrolase AcEst1 and its mutant of the present invention have the function of enantioselectively resolving methyl 3-cyclohexene-1-carboxylate with high efficiency to prepare optically active (S)-3-cyclohexene-1-carboxylic acid. When the substrate concentration is as high as 2000 mM (about 280 g/L), the optical purity of the product is higher than 99%, and the substrate/catalyst is as high as 3500 g/g. As compared with other preparation methods, the product prepared by the method of the present invention has high concentration and high optical purity, the catalytic efficiency is high, the reaction conditions are mild. Furthermore, the method is environmentally friendly, simple in operation and easy for industrial scale-up, thus has a good prospect of application in industry.

The present invention discloses a cyclohexenecarboxylate ester hydrolase, and a mutant, a coding gene, an expression vector, recombinant bacterium and use thereof. The cyclohexenecarboxylate ester hydrolase AcEst1 and its mutant of the present invention have the function of enantioselectively resolving methyl 3-cyclohexene-1-carboxylate with high efficiency to prepare optically active (S)-3-cyclohexene-1-carboxylic acid. When the substrate concentration is as high as 2000 mM (about 280 g/L), the optical purity of the product is higher than 99%, and the substrate/catalyst is as high as 3500 g/g. As compared with other preparation methods, the product prepared by the method of the present invention has high concentration and high optical purity, the catalytic efficiency is high, the reaction conditions are mild. Furthermore, the method is environmentally friendly, simple in operation and easy for industrial scale-up, thus has a good prospect of application in industry.